Revolution Medicines Inc (RVMD): Next-Year EPS Estimate 29.06%
As of 2026-06-04, Revolution Medicines Inc (RVMD) has a next-year EPS growth estimate of 29.06%.
On 2026-06-02, analyst consensus for RVMD's next-year EPS growth shifted from 28.78% to 29.06% — a positive change of 0.28 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at -33.82%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 29.06%
- EPS growth this year
- -33.82%
- EPS next quarter (est)
- -$1.96
- Last price
- $155.69
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 29.06% | -33.82% | -$1.96 | $155.69 |
| 2026-06-03 | 29.06% | -33.82% | -$1.96 | $155.99 |
| 2026-06-02 | 29.06% | -33.82% | -$1.96 | $151.31 |
| 2026-06-01 | 28.78% | -33.87% | -$1.96 | $163.68 |
| 2026-05-31 | 28.44% | -33.07% | -$1.93 | $157.48 |
| 2026-05-28 | 28.44% | -33.07% | -$1.93 | $154.63 |
| 2026-05-27 | 28.44% | -33.07% | -$1.93 | $153.00 |
| 2026-05-26 | 28.44% | -33.07% | -$1.93 | $154.89 |
| 2026-05-25 | 28.44% | -33.07% | -$1.93 | $151.56 |
| 2026-05-24 | 28.44% | -33.07% | -$1.93 | $151.56 |
| 2026-05-21 | 28.29% | -33.40% | -$1.93 | $153.73 |
| 2026-05-20 | 28.29% | -33.40% | -$1.93 | $150.33 |
| 2026-05-19 | 28.29% | -33.40% | -$1.93 | $147.30 |
| 2026-05-18 | 28.29% | -33.40% | -$1.93 | $144.37 |
| 2026-05-17 | 29.95% | -33.01% | -$1.92 | $145.66 |
| 2026-05-14 | 29.95% | -33.01% | -$1.92 | $149.47 |
| 2026-05-13 | 29.95% | -33.01% | -$1.92 | $148.61 |
| 2026-05-12 | 29.95% | -33.01% | -$1.92 | $145.72 |
| 2026-05-11 | 29.95% | -33.01% | -$1.92 | $144.15 |
| 2026-05-10 | 29.95% | -33.01% | -$1.92 | $141.81 |
| 2026-05-07 | 29.95% | -33.01% | -$1.92 | $142.51 |
| 2026-04-22 | 26.76% | -28.09% | -$1.84 | $141.50 |
Recent News
- Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens CaseGuruFocus.com
- RVMD Stock Jumps Overnight: New Drug Heads To FDA After Unprecedented 1-Year Survival Win In Pancreatic CancerStocktwits
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic CancerGlobeNewswire
- ASCO26: 5 data snapshots ahead of the years biggest cancer drug meetingBioPharma Dive
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO PresentationGlobeNewswire
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewswire
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswire
- Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual MeetingGlobeNewswire
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual MeetingGlobeNewswire
- Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual MeetingGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Revolution Medicines Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Revolution Medicines Inc (RVMD) has a next-year EPS growth estimate of 29.06%, based on analyst consensus.
When was the latest EPS estimate revision for RVMD?▾
The most recent revision occurred on 2026-06-02, when analysts adjusted the next-year EPS growth estimate from 28.78% to 29.06%.
What sector and industry does Revolution Medicines Inc belong to?▾
Revolution Medicines Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RVMD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Revolution Medicines Inc (RVMD) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports